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To identify genes influencing age at onset (AAO) in two common neurodegenerative diseases, a genomic screen
was performed for AAO in families with Alzheimer disease (AD; ) and Parkinson disease (PD; ).np 449 np 174
Heritabilities between 40%–60% were found in both the AD and PD data sets. For PD, significant evidence for
linkage to AAO was found on chromosome 1p (LOD p 3.41). For AD, the AAO effect of APOE (LOD p 3.28)
was confirmed. In addition, evidence for AAO linkage on chromosomes 6 and 10 was identified independently in
both the AD and PD data sets. Subsequent unified analyses of these regions identified a single peak on chromosome
10q between D10S1239 and D10S1237, with a maximum LOD score of 2.62. These data suggest that a common
gene affects AAO in these two common complex neurodegenerative diseases.
Introduction
Genetic studies of common complex neurodegenerative
diseases, such as Alzheimer disease (AD [MIM 104300])
and Parkinson disease (PD [MIM 168600]), have fo-
cused on the identification of risk genes as targets for
development of new treatments and improved diagnoses.
This approach has identified the amyloid precursor pro-
tein (APP) (Goate et al. 1991), presenilin 1 (PS1) (Sher-
rington et al. 1995), presenilin 2 (PS2) (Levy-Lahad et
al. 1995; Rogaev et al. 1995), and apolipoprotein E
(APOE) (Corder et al. 1993) genes as contributing to
risk in AD. APP, PS1, and PS2 cause rare early-onset
autosomal dominant AD (5% of AD cases), whereas
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APOE is associated with both risk and age at onset
(AAO) in late-onset familial AD, as well as in late- and
early-onset sporadic AD. Similarly, three genes have been
identified to associate with risk in PD: a-synuclein (Po-
lymeropoulos et al. 1996) for rare autosomal dominant
early-onset PD, Parkin (Abbas et al. 1999) for rare au-
tosomal recessive juvenile parkinsonism and autosomal
recessive early-onset PD, and tau (Martin et al. 2001)
for classic PD. Genomic screens in both PD (Destefano
et al. 2001; Scott et al. 2001) and AD (Kehoe et al. 1999;
Pericak-Vance et al. 2000) have recently localized ad-
ditional—but, as yet, unknown—risk genes.
However, risk is only one mode of genetic expression;
AAO of disease may also be genetically influenced and
may have an effect equivalent to that seen for the known
risk genes (Daw et al. 2000). Identification of such genes
would open new avenues of research with the potential
to delay onset beyond the natural life span. Present
knowledge about genes contributing to AAO in neu-
rodegenerative diseases clearly lags behind the under-
standing of genes contributing to risk. Recently, there
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Table 1
Description of Data Sets
CHARACTERISTIC
VALUE FOR DATA SET
AD PD ADPD
No. of families 449 174 623
No. of affected individuals with reported AAO information 1,121 378 1,499
No. of unaffected individuals with reported AAE
information 746 470 1,216
Mean  SD reported AAO, in years (range) 72.8  6.8 (49–97) 60.1  12.7 (12–90) 69.6  10.3 (12–97)
Mean  SD reported AAE, in years, from unaffected indi-
viduals (range) 70.2  13.0 (29–105) 68.4  12.7 (34–98) 69.6  12.9 (29–105)
has been growing interest in using AAO information as
a quantitative trait, to identify genes that influence onset
of disease (Daw et al. 1999, 2000; Duggirala et al.
1999). Rapid development of methods of mapping
quantitative trait loci (QTLs) for general pedigrees
(Goldgar 1990; Amos 1994; Blangero and Almasy
1997) has nowmade the search for novel genes affecting
AAO feasible.
In this study, the variance-component procedure in
SOLAR (Blangero and Almasy 1997) was used to per-
form genomewide scans on the quantitative trait AAO
for AD and PD to map QTLs influencing AAO. This
method is less penetrance-model dependent than the
classical segregation/linkage-mapping technique, and it
can take into account covariate or random effects. The
common regions showing evidence of linkage from in-
dependent analyses of AD and PD data sets were an-
alyzed further by use of the combined AD and PD data
set. Because AD and PD share some common clinical
and pathological findings, we hypothesized that a gene
or genes common to both disorders control AAO and
could be localized by use of this genomic-screening
approach.
Material and Methods
Family Ascertainment
In this study, we used a total of 449 families affected
with AD and 174 families affected with PD. Ascertain-
ment of data from families with AD and PD was in-
dependently conducted by various research centers. The
data from families with AD were ascertained by the fol-
lowing centers: the Duke Center for Human Genetics
(CHG); the Joseph and Kathleen Bryan Alzheimer’s Dis-
ease Research Center (Bryan ADRC); the Indiana Alz-
heimer’s Disease Research Center National Cell Repos-
itory (IADRC); the National Institute of Mental Health
(NIMH); and Vanderbilt University (VAN). In all data
sets, affected individuals were classified in accordance
with the National Institute of Neurological and Com-
municative Disorders and Stroke and the Alzheimer’s
Disease and Related Disorders Associations (NINCDS-
ADRDA) clinical diagnostic criteria (McKhann et al.
1984). The reported AAO of patients with AD was de-
fined as the age at which the caregiver, family, and/or
individual first noted cognitive problems (most often
short-term memory loss and, more rarely, other prob-
lems, such as dysphasia or disorientation to time or
place, followed closely by memory change) sufficient to
interfere with independent daily activities. The data from
families with PD were ascertained by 13 centers in the
United States and Australia (see Scott et al. 2001). Di-
agnostic and exclusion criteria, based on previously pub-
lished diagnostic criteria for PD (Ward and Gibb 1990;
Hughes et al. 1992a, 1992b), were adopted by all par-
ticipating clinicians before beginning selection of fami-
lies. Affected individuals were defined by having at least
two cardinal signs of PD (e.g., rest tremor, bradykinesia,
and rigidity) and no atypical clinical features or other
causes of parkinsonism. The reported AAO was defined
as the age at which an affected individual first noticed
one of the cardinal signs of PD. In both AD and PD
ascertainment, the reported AAE was recorded as the
age at which study personnel clinically examined a par-
ticipant. The data description is summarized in table 1.
Overall, for AD, we have 1,121 affected individuals with
reported AAO and 746 unaffected individuals with re-
ported AAE, and, for PD, we have 378 affected indi-
viduals with reported AAO and 470 unaffected individ-
uals with reported AAE. Average reported AAO  SD
was 72.8  6.8 years for AD and 60.1  12.7 years
for PD. Average reported AAE for unaffected individuals
was 70.2  13.0 years for AD and 68.4  12.7 years
for PD. All participants or their legal representatives
gave informed consent prior to joining the study, and
data were collected according to protocols approved by
each contributing group’s institutional review board.
Modeling AAO Data
We modeled AAO data as described by Duggirala et
al. (1999), where AAO was suggested as a right-trun-
cated quantitative trait in affected individuals (i.e., re-
ported AAO is less than or equal to reported AAE) and
a left-truncated quantitative trait in unaffected individ-
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Table 2
Residual Heritability (SE) of the AAO for Each Data Set under
Each Model
DATA
SET
RESIDUAL HERITABILITYa [SE]
(%)
PROPORTION OF
VARIANCE
CONTRIBUTED
BY ALL COVARIATES
Model 1 Model 2 Model 1 Model 2
AD 41.8% [.038] … 0.9% …
PD 61.3% [.044] … 15.3% …
ADPD 55.7% [.028] 49.2% [.029] 1.8% 8.3%
NOTE.—The polygenic models are: model 1, covariate at sex
and affection status; and model 2, covariate at sex, affection
status, and disease.
a The residual heritability is the ratio of the residual variance
(after removing the covariate effects) to the total phenotypic
variance.
uals (i.e., reported AAO is greater than reported AAE).
That is, the AAO data was comprised of reported AAO
for affected individuals and reported AAE for unaffected
individuals. Outliers and normality of the data were ex-
amined for agreement with the assumption of QTL anal-
ysis. Four outliers that were 4 SD below the mean AAO
were excluded in the AD data set.
Linkage Analysis
We used the variance-components procedure in SO-
LAR (Almasy and Blangero 1998) for linkage analysis.
In theory, the quantitative phenotype AAO (y) was de-
fined as a linear function of the nQTLs ( ) that influenceri
the trait:
n
yp mXb r  e , i
ip1
where X is a matrix of covariates and b is the regression
coefficient matrix associated with the covariates. The
phenotype is assumed to follow a normal distribution.
The likelihood function of y includes the identical by
descent (IBD) probability at a marker that is linked to
a QTL, the additive genetic variance attributed by an
unobserved QTL ( ), and other variance components.2jq
SOLAR employs the likelihood-ratio test to test a null
hypothesis of (no linkage) and generates a LOD2j p 0q
score that is the equivalent of the classical LOD score
of linkage analysis. This technique can be applied to
detect the evidence of linkage to an individual marker
for two-point analysis or to an imputed chromosomal
position in multipoint analysis. Locus-specific IBD in-
formation for pairs of relatives was obtained prior to
computation of the likelihood function. The multipoint
mapping strategy in SOLAR is an extension of the
method of Fulker et al. (1995). It requires the map dis-
tance between the markers to create the IBD information
of a pair of relatives at a QTL that is linked to a marker.
We used a Kosambi sex-averaged map obtained from
Map-O-Mat (Lander and Green 1987;Matise and Gitlin
1999). The linkage analysis method implemented in SO-
LAR does not require specification of disease-allele fre-
quency, penetrance, or mode of inheritance, which dif-
fers from the classical linkage mapping procedure.
The initial genomic screens were performed on an AD
data set of 449 families with a total of 4,316 relative
pairs (sib pairs, cousin pairs, avuncular pairs, etc.) and
a PD data set of 174 families with 2,256 relative pairs.
A total of 323 (AD) and 330 (PD)microsatellitemarkers,
with an average spacing of 10 cM, were analyzed (Vance
and Ben Othmane 1998). Since AAO was modeled as a
truncated quantitative trait, the overall distribution of
AAO was thus considered as a mixture of two truncated
normal distributions. We included sex and affection
status as covariates in the polygenic model (model 1),
in which affection status was used for adjustment of the
contribution of reported AAO and reported AAE to the
quantitative trait AAO.
The common interesting (see below) regions identified
by the initial linkage analyses of AD and PD data sets
were followed up by use of the combined AD and PD
(ADPD) data set for linkage analysis. There are many
reasons to consider the hypothesis of similar genetic
mechanisms leading to AAO in AD and PD. Both AD
and PD are neurodegenerative, late-AAO disorders.
Clinically, a significant number of patients with AD de-
velop signs of parkinsonism, including bradykinesia, ri-
gidity, and gait abnormalities (Wilson et al. 2000). Con-
versely, dementia is a major factor in PD, and the two
disorders both exhibit degeneration of cholinergic neu-
rons in the nucleus basalis of Meynert (Korczyn 2001).
Another pathological similarity is the presence of similar
staining a-synuclein Lewy bodies (LB) in both disorders,
supporting the premise that the two diseases may share
a common pathway leading to LB formation (Lippa et
al. 2001). APOE, a well-proven risk factor for AD, has
been suggested, in some studies (e.g., Harhangi et al.
2000), to be involved in the risk for PD as well, although
others have failed to confirm these findings (Khan et al.
2001). In addition, frontotemporal dementia-17, caused
by mutations in the tau gene, presents phenotypically
with a dementia similar to AD coupled with parkinson-
ism (McKhann et al. 2001). The tau gene, a major el-
ement in the neurofibulary tangles of AD, has recently
been shown to be associated with PD as well (Martin
et al. 2001). These similarities are likely not derived from
the biologic events that initiate the start of each disease
but rather from overlapping neuropathic pathways in-
volved in the progression of each disorder. It is these
same pathways and modifier genes that are likely to
contribute to phenotypic traits such as AAO, which is
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why we pooled these two neurodegenerative diseases for
a combined analysis.
For the analysis of the ADPD data set, two polygenic
models were considered, to incorporate two different
scenarios:
Model 1.—We assumed that AD and PD are the same
disease, so sex and affection status were included as cov-
ariates as that in the initial linkage analysis.
Model 2.—We considered that the distribution of the
ADPD data set is a mixture of two normal distributions
(AAO from AD and AAO from PD), so disease status
was included as an additional covariate, to distinguish
the different contribution of AAO between AD and PD.
Results
Polygenic Models Revealed Strong Heritability of AAO
Genes
The analyses of polygenic models showed that sex,
affection status, and disease were all significant covar-
iates, for instance, with P values !.0001 for the ADPD
data set. The proportion of variance contributed by all
covariates included in the model ranged from 0.9% to
15.3% among different data sets (table 2). We found
that the AD data set showed the smallest proportion of
variance from all covariates (0.9%). This may be due to
the larger sample size for AD than for PD or to the
marginally significant effect of sex and affection status
in AD ( for sex and for affection status).Pp .03 Pp .05
The heritability of AAO after these covariates were con-
trolled for was highly significant in each of the data sets
( ), with heritabilities of 42% (AD), 62% (PD),P ! .0001
56% (ADPD, model 1), and 49% (ADPD, model 2)
(table 2). These data strongly indicate that genes are
important modulators of AAO.
Disease-Specific Linkage Evidence
The initial linkage analyses were performed on the AD
and PD data sets separately. A threshold of LOD 11.00
was used for declaring a region “interesting” (table 3)
(Weeks et al. 2000) and warranting follow-up analyses.
Of greatest interest for PD is the result on chromosome
1, near D1S2134 (78 cM; ). For AD, ex-LODp 3.41
amination of APOE, a known modulator of AAO in AD
(Corder et al. 1993), generated a LOD score of 3.28 in
the AD data set, confirming its role as a modulator of
AAO. In addition to APOE, strong AD-specific suggestive
linkage regions on chromosome 4q at D4S1652 (208 cM;
) and chromosome 8q (150 cM,LODp 2.29 LODp
) were also found. Interestingly, neither chromosome2.09
4q nor chromosome 8q have been reported as linkage
regions with AD risk genes. It is possible that chromo-
somes 4q and 8q harbor genes that exclusively modulate
onset of AD.
Linkage Evidence for a Common AAO Gene on
Chromosome 10q
We found that, in the initial genomic screens, chro-
mosomes 6 and 10 gave evidence for linkage to AAO
in both the AD and PD data sets (table 3). The peaks
were 12 cM apart on chromosome 6 (51 cM in AD and
63 cM in PD) and were 7 cM apart on chromosome 10
(132 cM in PD and 139 cM in AD). To decipher the
role of these common interesting linkage regions, we
performed linkage analyses on the combined ADPD data
set for chromosomes 6 and 10. Analysis of the ADPD
data set by use of models 1 and 2 did not result in a
consistent area of interest for chromosome 6, as the com-
bined data set gave peak LOD scores of 1.96 at 154 cM
for model 1 and 1.81 at 156 cM for model 2. This peak
from the combined ADPD data set is unlinked to both
the independent AD (51 cM) and PD (63 cM) regions.
However, analysis of the ADPD data set on chromosome
10 confirmed the findings from the analyses of the in-
dependent AD and PD data sets, resulting in a single
peak region on chromosome 10q between D10S1239
and D10S1237, with LOD scores of 2.33 for model 1
at 133 cM and 2.62 for model 2 at 135 cM (table 3).
Figure 1 summarizes the multipoint results of the four
analyses on chromosome 10. As can be seen, four anal-
yses revealed a similar pattern of LOD scores across
chromosome 10, with a single peak region. Notably,
inclusion of disease status as a covariate in model 2
slightly increases the LOD score in the ADPD data set.
Our results strongly suggest that a common modulator
of AAO for AD and PD may be located on chromosome
10q.
Discussion
Genomic screens have concentrated historically on iden-
tifying genes controlling the risk of developing a disease.
However, risk is not the only important aspect of a dis-
ease. Onset of disease is also crucial, as understanding
the regulation of onset could make it possible to delay
onset beyond an individual’s normal life span. The re-
sults of this study, the first genomic screens for AAO in
two major neurodegenerative diseases (AD and PD),
demonstrate that AAO is highly heritable and that the
search for AAO genes is possible. It should be noted that
AAO data are very difficult to acquire reliably, and false-
negative results may be produced. With this point in
mind, this study followed published standards in ascer-
tainment for definition of reported AAO for affected
individuals and reported AAE for a participant. In ad-
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Table 3
Summary of the Peak Regions with LOD 11 from the Multipoint Analysis
CHROMOSOME AND
MARKER REGION
MAP
POSITIONa
(cM)
LOD (DISTANCE) IN DATA SET
ADPD
AD PD Model 1 Model 2
Chromosome 1:
D1S2134 76
Peak 78 3.41
D1S200 82
Chromosome 4:
Peak (D4S1652) 208 2.29
Chromosome 5:
D5S1462 105
Peak 108 1.65
D5S1453 115
Chromosome 6:
D6S2439 43
Peak 51 1.17
D6S2427 54
Peak (D6S1017) 63 1.88
GATA184A08 146
Peak 154/156 1.96 (154 cM) 1.81 (156 cM)
D6S1007 160
Chromosome 8:
D8S1128 140
Peak 150 2.09
D8S373 165
Chromosome 10:
Peak (D10S1239) 132 1.55
Peak 133/135 2.33 (135 cM) 2.62 (133 cM)
Peak (D10S1237) 139 2.39
Chromosome 13:
Peak (D13S800) 55 1.41
Peak (D13S285) 111 1.46
Chromosome 17:
Peak (D17S1303) 25 1.93
Chromosome 18:
Peak (D18S877) 54 1.33
Chromosome 20:
D20S851 25
Peak 27 1.47
D20S604 33
Chromosome 22:
Peak (D22S683) 37 1.32
a The map positions are based on the sex-averaged distance, in Kosambi centimor-
gans, in Map-O-Mat.
dition, the large sample sizes assembled for both AD and
PD should help to decrease the false-negative outcome.
Although some limitations may exist, overall, we believe
that our data set has significant power to detect genes
modulating AAO.
Elsewhere, Daw et al. (2000) reported that at least
four AAO genes with effect size possibly equal to or
greater than that of APOE exist. However, the chro-
mosomal locations linked to these putative AAO genes
are still unknown. The present genomic screen for AAO
in AD has identified six suggested linkage regions for
AAO, in which chromosomes 4q, 8q, and 10q show
the most promising results, with LOD scores 12. The
APOE gene still yielded the strongest linkage effect
among the newly identified regions in AD, and the role
of APOE in controlling onset of AD was further con-
firmed. For PD, we identified a single peak with very
strong linkage evidence ( ) near D1S2134LODp 3.41
(78 cM). Previously, Valente et al. (2001) and van Duijn
et al. (2001) had localized genes for rare autosomal
recessive early-onset PD to two independent regions on
chromosome 1p (PARK6 and PARK7, respectively). The
minimal candidate region (MCR) for PARK6 defined
by the observed recombination in the family is between
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Figure 1 Results of chromosome 10 multipoint linkage analyses. Marker distances were based on sex-averaged Kosambi centimorgans
according to Map-O-Mat.
D1S483 (45.3 cM) and D1S247 (57.8 cM), whereas the
MCR for PARK7 is between D1S468 (4.2 cM) and
D1S214 (14 cM). In addition, the weak support for
linkage on chromosome 1q ( at 214 cM)LODp 1.20
to PD risk reported by DeStefano et al. (2001) is un-
linked to our region.
Several recent reports have focused attention on chro-
mosome 10q for AD (Bertram et al. 2000; Ertekin-Taner
et al. 2000; Myers et al. 2000; Haines and Pericak-Vance
2001) but have been inconsistent in localization (fig. 2).
Only the region identified by Bertram et al. (2000) by
use of the NIMH family-sample data set maps near our
region. To clarify our results, we further tested two sub-
sets of data: a subset of the AD data, made up of all the
NIMH families (∼60% of the overall AD data set), and
a combined ADPD data set, without NIMH data, for
chromosome 10. First, the NIMH AD subset generated
a LOD score of 1.00 near D10S677, which is adjacent
to D10S1239 (6 cM apart). The remaining non-NIMH
data set thus contributed equally to the overall LODscore
in AD. Second, the combined ADPD data set without
NIMH data generated LOD scores of 1.48 for model 1
and 1.55 for model 2, at D10S1239 (132 cM). Figure 2
depicts the map positions of published linkage regions
for risk genes on chromosome 10q and our linkage find-
ings for AAO genes. It is clear that the linkage effect on
chromosome 10q spans the different data sets used in the
analyses. Three independent risk-gene studies (Ertekin-
Taner et al. 2000; Myers et al. 2000; Pericak-Vance et
al. 2000; Haines and Pericak-Vance 2001) identified an
overlapping region (between D10S1225 and D10S1211)
that is ∼47 cM proximal to our linkage region for AAO.
Only NIMH data showed an overlapping linkage region
for both risk and AAO genes. Our findings suggest three
possible explanations for the previously reported incon-
sistent localizations of risk genes on chromosome 10
(Myers et al. 2000): (1) the same gene may affect both
risk and onset in a subset of families, (2) onset and risk
may be affected by separate genes within this region, or
(3) the statistical methods may be detecting the genetic
effects on onset when studying risk. Until the results can
be replicated in different data sets, it is difficult to draw
a conclusion at this stage to explain the inconsistent lo-
calization reported on chromosome 10. In addition, po-
tential differences across ascertainment centers were in-
vestigated in our analysis by treating center as a random
effect in the analyses. The center effect was not significant
in PD but was significant in AD, with 1.9% heritability.
After including the center effect for the AD data, the same
peak region (near D10S1237) was found, with LODp
2.03. These results confirmed that ascertainment through
multiple centers is unlikely to significantly bias our find-
ings on chromosome 10. For PD, no risk genes have yet
been reported on chromosome 10 (Scott et al. 2001).
Our study is the first to link chromosome 10q to PD.
AD and PD, although distinct clinical entities, share
some common clinical and pathological features. Both
have substantial variability in AAO. Although Lewy
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Figure 2 Map positions of reported linkage results for the risk
and AAO genes on chromosome 10q.
bodies are a cardinal feature of PD (Lippa et al. 2001),
they can be found in individuals with autopsy-con-
firmed AD (Hulette et al. 2000; Scott et al. 2000). De-
mentia is the primary feature of AD, but a substantial
number of patients with PD also develop dementia as
their PD progresses (Scott et al. 2001). Thus, it is pos-
sible that AD and PD share common etiologic pathways.
The use of combined AD and PD data sets for linkage
analysis is therefore justified. The results presented here
point to one or more genes on chromosome 10 as a
common modulator of AAO in these neurodegenerative
diseases.
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